Kahn Swick & Foti, LLC ("KSF") reminds investors of the February 10, 2025, deadline to file as lead plaintiffs in the class action lawsuit against Cassava Sciences, Inc. (NasdaqCM: SAVA). The lawsuit alleges that Cassava failed to disclose material information during the Class Period (February 7, 2024–November 24, 2024). On November 25, 2024, the company reported that its drug simufilam failed to meet key endpoints in a Phase 3 trial, causing an 83% stock price drop from $26.48 to $4.30 per share.